Dr. Reddy's Laboratories announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
Dr. Reddy's Versavo® is a (bevacizumab) biosimilar of Avastin®1 and indicated for the treatment of several types of cancers, including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian cancer and metastatic breast cancer.
Versavo® is the first Dr. Reddy's biosimilar product to be approved and launched in the UK. It is available in strengths of 100mg and 400mg single use vials.
Dr. Reddy's launched Versavo® in India in 2019. Subsequently, Versavo® was introduced in other markets such as Thailand, Ukraine, Nepal, and Jamaica under the same brand name. In Colombia, the product was launched under the brand name Persivia®.